Materials engineering for immunomodulation

The engineering of materials that can modulate the immune system is an emerging field that is developing alongside immunology. For therapeutic ends such as vaccine development, materials are now being engineered to deliver antigens through specific intracellular pathways, allowing better control of the way in which antigens are presented to one of the key types of immune cell, T cells. Materials are also being designed as adjuvants, to mimic specific 'danger' signals in order to manipulate the resultant cytokine environment, which influences how antigens are interpreted by T cells. In addition to offering the potential for medical advances, immunomodulatory materials can form well-defined model systems, helping to provide new insight into basic immunobiology.

[1]  Kinam Park,et al.  Complement activation by PEO-grafted glass surfaces. , 1999, Journal of biomedical materials research.

[2]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. Belz,et al.  Cross‐presentation, dendritic cell subsets, and the generation of immunity to cellular antigens , 2004, Immunological reviews.

[4]  Eva M. Sevick-Muraca,et al.  Virus-like Particle (VLP) Lymphatic Trafficking and Immune Response Generation After Immunization by Different Routes , 2009, Journal of immunotherapy.

[5]  D. Irvine,et al.  Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. , 2008, Biomaterials.

[6]  R. Steinman,et al.  Differential Antigen Processing by Dendritic Cell Subsets in Vivo , 2007, Science.

[7]  Kevin Braeckmans,et al.  Extracellular barriers in respiratory gene therapy☆ , 2008, Advanced Drug Delivery Reviews.

[8]  Polly Matzinger,et al.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.

[9]  G. Belz,et al.  Most lymphoid organ dendritic cell types are phenotypically and functionally immature. , 2003, Blood.

[10]  P. Roy,et al.  Virus‑like particles as a vaccine delivery system: Myths and facts , 2008, Human vaccines.

[11]  J. Villadangos,et al.  Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo , 2007, Nature Reviews Immunology.

[12]  Francesco Stellacci,et al.  Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. , 2008, Nature materials.

[13]  Ravi V. Kolla,et al.  Complement C3d Conjugation to Anthrax Protective Antigen Promotes a Rapid, Sustained, and Protective Antibody Response , 2007, PloS one.

[14]  Colin R. F. Monks,et al.  Three-dimensional segregation of supramolecular activation clusters in T cells , 1998, Nature.

[15]  E. Pearce,et al.  MHC class II–dependent basophil–CD4+ T cell interactions promote TH2 cytokine–dependent immunity , 2009, Nature Immunology.

[16]  A. Hoffman,et al.  Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. , 2009, Bioconjugate chemistry.

[17]  Martin Müller,et al.  Oxidation-responsive polymeric vesicles , 2004, Nature materials.

[18]  F. Re,et al.  Aluminum Hydroxide Adjuvants Activate Caspase-1 and Induce IL-1β and IL-18 Release1 , 2007, The Journal of Immunology.

[19]  Christopher C. Goodnow,et al.  C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.

[20]  R. Steinman,et al.  Dendritic cells: translating innate to adaptive immunity. , 2006, Current topics in microbiology and immunology.

[21]  Melody A. Swartz,et al.  Dendritic-cell trafficking to lymph nodes through lymphatic vessels , 2005, Nature Reviews Immunology.

[22]  Sandra L. Schmid,et al.  Regulated portals of entry into the cell , 2003, Nature.

[23]  G. Núñez,et al.  The Nlrp3 inflammasome is critical for aluminium hydroxide‐mediated IL‐1β secretion but dispensable for adjuvant activity , 2008, European journal of immunology.

[24]  P. Godowski,et al.  Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines , 2002, The Journal of Immunology.

[25]  D. Oupický,et al.  Multiblock reducible copolypeptides containing histidine-rich and nuclear localization sequences for gene delivery. , 2006, Bioconjugate chemistry.

[26]  J. Demeester,et al.  Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus , 2002, Gene Therapy.

[27]  D. Irvine,et al.  Directed cell migration via chemoattractants released from degradable microspheres. , 2005, Biomaterials.

[28]  Manmohan J. Singh,et al.  Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. , 2006, Current drug delivery.

[29]  V. Villeret,et al.  Deletion of Flagellin’s Hypervariable Region Abrogates Antibody-Mediated Neutralization and Systemic Activation of TLR5-Dependent Immunity1 , 2008, The Journal of Immunology.

[30]  A. Rot,et al.  CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells , 2007, The Journal of experimental medicine.

[31]  T. Bieber,et al.  Toll-like receptor 7 agonists and skin. , 2008, Drug news & perspectives.

[32]  Robert B Sim,et al.  The covalent-binding reaction of complement component C3. , 1981, The Biochemical journal.

[33]  R. Steinman,et al.  The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing , 1995, Nature.

[34]  K. Sheng,et al.  Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo , 2008, European journal of immunology.

[35]  J. Irache,et al.  Salmonella-like bioadhesive nanoparticles. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Joel A. Cohen,et al.  T-cell activation by antigen-loaded pH-sensitive hydrogel particles in vivo: the effect of particle size. , 2009, Bioconjugate chemistry.

[37]  Jeffrey A Hubbell,et al.  PEG-b-PPS diblock copolymer aggregates for hydrophobic drug solubilization and release: cyclosporin A as an example. , 2008, Molecular pharmaceutics.

[38]  M. Swartz,et al.  The physiology of the lymphatic system. , 2001, Advanced drug delivery reviews.

[39]  J. Hanes,et al.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.

[40]  J. Tschopp,et al.  Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome , 2009, Proceedings of the National Academy of Sciences.

[41]  Manmohan J. Singh,et al.  Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. , 2009, Advanced drug delivery reviews.

[42]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[43]  Soong Ho Um,et al.  Cytosolic delivery mediated via electrostatic surface binding of protein, virus, or siRNA cargos to pH-responsive core-shell gel particles. , 2009, Biomacromolecules.

[44]  K. Mossman,et al.  Altered TCR Signaling from Geometrically Repatterned Immunological Synapses , 2005, Science.

[45]  R. Cone,et al.  Barrier properties of mucus. , 2009, Advanced drug delivery reviews.

[46]  Justin Hanes,et al.  Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus , 2007, Proceedings of the National Academy of Sciences.

[47]  E. Smiley,et al.  Low molecular weight disulfide cross-linking peptides as nonviral gene delivery carriers. , 2000, Bioconjugate chemistry.

[48]  S. Standley,et al.  Fully acid-degradable biocompatible polyacetal microparticles for drug delivery. , 2008, Bioconjugate chemistry.

[49]  R. Medzhitov,et al.  Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.

[50]  M. van Lookeren Campagne,et al.  Macrophage complement receptors and pathogen clearance , 2007, Cellular microbiology.

[51]  Jung Soo Suk,et al.  Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. , 2008, Angewandte Chemie.

[52]  Y. Huang,et al.  Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[53]  I. Sjöholm,et al.  Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice. , 2004, Vaccine.

[54]  R. Steinman,et al.  The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. , 2008, The Journal of clinical investigation.

[55]  N. Peppas,et al.  A theory of molecular diffusion in the intestinal mucus , 1984 .

[56]  J. Hubbell,et al.  Breakdown kinetics of aggregates from poly(ethylene glycol-bl-propylene sulfide) di- and triblock copolymers induced by a non-ionic surfactant , 2008 .

[57]  Bali Pulendran,et al.  The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). , 2009, Biomaterials.

[58]  A. Alshamsan,et al.  Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. , 2008, Vaccine.

[59]  L. Thomsen,et al.  Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. , 2004, Vaccine.

[60]  Junying Yuan,et al.  Divergence from a dedicated cellular suicide mechanism: exploring the evolution of cell death. , 2006, Molecular cell.

[61]  J. Fréchet,et al.  Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.

[62]  J. Hubbell,et al.  A New Living Emulsion Polymerization Mechanism: Episulfide Anionic Polymerization , 2002 .

[63]  N. Shastri,et al.  In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[64]  A. Goldman,et al.  Structure of complement factor H carboxyl‐terminus reveals molecular basis of atypical haemolytic uremic syndrome , 2006, The EMBO journal.

[65]  Manmohan J. Singh,et al.  The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. , 2008, Journal of pharmaceutical sciences.

[66]  Antal Rot,et al.  CCR7 and its ligands: balancing immunity and tolerance , 2008, Nature Reviews Immunology.

[67]  M. Carroll,et al.  The complement system in regulation of adaptive immunity , 2004, Nature Immunology.

[68]  Junsang Doh,et al.  Immunological synapse arrays: patterned protein surfaces that modulate immunological synapse structure formation in T cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[69]  D. Busch,et al.  TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. , 2008, Vaccine.

[70]  Y. Ikada,et al.  Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. , 1994, Journal of pharmaceutical sciences.

[71]  F. Young.  Biochemistry , 1955, The Indian Medical Gazette.

[72]  R. Medzhitov,et al.  On regulation of phagosome maturation and antigen presentation , 2006, Nature Immunology.

[73]  M. Newman,et al.  Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations. , 1997, Vaccine.

[74]  Berni Dwan,et al.  Myths and facts , 2000 .

[75]  Myeong Sup Lee,et al.  Pattern-recognition receptor signaling initiated from extracellular, membrane, and cytoplasmic space. , 2007, Molecules and cells.

[76]  Ashutosh Kumar Singh,et al.  Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[77]  Jeffrey A Hubbell,et al.  PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery. , 2007, Biomacromolecules.

[78]  J. Hubbell,et al.  Interfacial reactivity of block copolymers: understanding the amphiphile-to-hydrophile transition. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[79]  Darrell J Irvine,et al.  Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. , 2007, Nano letters.

[80]  J. Tschopp,et al.  Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica , 2008, Science.

[81]  M. Jenkins,et al.  The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. , 2007, Immunity.

[82]  P. Marche,et al.  Amplification of the antibody response by C3b complexed to antigen through an ester link. , 1998, Journal of immunology.

[83]  Myeong Sup Lee,et al.  Signaling pathways downstream of pattern-recognition receptors and their cross talk. , 2007, Annual review of biochemistry.

[84]  N. Peppas,et al.  Gel-gel adhesion by tethered polymers , 2001 .

[85]  E. Wagner,et al.  pH-responsive shielding of non-viral gene vectors , 2006, Expert opinion on drug delivery.

[86]  D. Irvine,et al.  Modular injectable matrices based on alginate solution/microsphere mixtures that gel in situ and co-deliver immunomodulatory factors. , 2008, Acta biomaterialia.

[87]  Joel A. Cohen,et al.  Enhanced cell penetration of acid-degradable particles functionalized with cell-penetrating peptides. , 2008, Bioconjugate chemistry.

[88]  M. Sixt,et al.  The microanatomy of T‐cell responses , 2008, Immunological reviews.

[89]  A. Rudensky,et al.  Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. , 2003, Immunity.

[90]  David J. Mooney,et al.  Infection-Mimicking Materials to Program Dendritic Cells In Situ , 2008, Nature materials.

[91]  Shixia Wang,et al.  Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model. , 2004, Vaccine.

[92]  J. Atkinson,et al.  T-cell regulation: with complements from innate immunity , 2007, Nature Reviews Immunology.

[93]  H. Elwing,et al.  Complement activation and inflammation triggered by model biomaterial surfaces. , 1998, Journal of biomedical materials research.

[94]  Antonio Lanzavecchia,et al.  Duration, combination and timing: the signal integration model of dendritic cell activation. , 2007, Trends in immunology.

[95]  Ira Mellman,et al.  Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.

[96]  P. Payette,et al.  Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities , 2004, European journal of immunology.

[97]  Samir Mitragotri,et al.  Role of target geometry in phagocytosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[98]  Qing Ge,et al.  Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines , 2004, Nature materials.

[99]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.